TB strains may be susceptible or resistant to isoniazid (i.e. MDR-TB), or resistant to other first-line TB medicines (polyresistant) or second-line TB medicines (e.g. extensively drug-resistant …

Multidrug-resistant tuberculosis (MDR-TB) is caused by bacteria that do not respond to, at least, isoniazid and rifampicin, the two most powerful anti-TB medicines.

Multidrug-resistant TB (MDR-TB): TB caused by M.tb strains that are resistant to both H and R with or without resistance to other first-line anti-TB drugs. MDR-TB patients also include …

Fourth, diagnosing MDR-TB cases among previously treated patients and providing effective treatment will greatly help in halting the spread of MDR-TB. This edition also addresses the …

In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that …

About 410,000 new cases of multidrug-resistant1 or rifampicin-resistant tuberculosis (MDR/RR-TB) were estimated to occur in 2022. While all of these would have been eligible for a second …

Fig. 2.4.2 Number of people diagnosed with MDR/RR-TB (blue) and enrolled on treatment for MDR/RR-TB (red), 2010–2022, 30 high MDR/RR-TB burden countries Globally, the …

Globally, MDR/RR-TB caused an estimated 160 000 (95% UI: 98 000–220 000) deaths in 2022. The reason why the number of people developing MDR/RR-TB is not estimated to have …

Case Definitions for MDR-TB and XDR-TB .....107 16.3. Data Collection Tools and Flow of Information ..................................................................109

The BPaL regimen for MDR-TB with additional fluoroquinolone resistance Recommendation 4.1 A treatment regimen lasting 6-9 months composed of bedaquiline, pretomanid and linezolid …